Impact of Clinical Pharmacist Diabetes Clinic on the Improvement of Health Outcomes in Type 2 Diabetes Subjects

Authors

  • Nawal AlSubaie Department of Pharmacy Practice, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia
  • Mohannad Alsallal Department of Pharmaceutical Services, Prince Sultan Military Medical City, Riyadh, Saudi Arabia https://orcid.org/0000-0002-7510-5742
  • Sulaiman AlTwaijri Department of Pharmaceutical Services, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
  • Ahmed AlOtaibi Department of Pharmaceutical Services, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
  • Bandar AlHarbi Department of Pharmaceutical Services, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
  • Mohammad AlEissa Department of Family and Community Medicine, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
  • Rana Alrashedi Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefah University, Riyadh, Saudi Arabia

DOI:

https://doi.org/10.3889/oamjms.2022.9518

Keywords:

Clinical pharmacist, Diabetes clinic, Ambulatory care clinic, Collaborative outcomes, Multidisciplinary, Type 2 diabetes mellitus

Abstract

AIM: This study aimed to evaluate the improvement of HbA1c, lipid profile, blood pressure readings, and weight in type 2 diabetes at the clinical pharmacist diabetes clinic (CPDC) in ambulatory care clinic.

METHODS: A retrospective study was conducted at a CPDC; the clinical pharmacist role was to follow-up the referred uncontrolled type 2 diabetes patients and providing comprehensive management.

RESULTS: A total of 419 patients were included the study. The mean ± standard error of the mean (SEM) age was 58.9 ± 0.59 years old. Sixty-two percent of the patients were female. At baseline, mean HbA1C ± SEM was 10.69% ± 0.06%, mean low-density lipoprotein (LDL) ± SEM was 2.66 ± 0.04 mmol/l. After 3 months of follow-up, HgbA1C had a statistically significant improvement by a reduction of 1.69% to be 9% ± 0.09% (95% confidence interval [CI] [1.50–1.87], p < 0.001). Moreover, mean HbA1C had a statistically significant improvement after 6 months of follow-up compared to baseline by 1.78% to be 8.9% ± 0.21% (95% CI [1.33–2.22], p < 0.001). LDL had a statistically significant improvement after 3 months by 0.24 mmol/l to be 2.42 ± 0.04 mmol/l (95% CI [0.15–0.35], p < 0.001) and after 6 months of follow-up by 0.28 mmol/l to be 2.38 ± 0.04 mmol/l (95% CI [0.20–0.36], p < 0.001).

CONCLUSION: The results stated that the clinical pharmacist anticipated care is achievable and had significant effect in the reduction of HbA1C and LDL levels in patients with uncontrolled type 2 diabetes.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Brussels, Belgium: International Diabetes Federation; 2021. p. 1-430.

Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843. https://doi.org/10.1016/j.diabres.2019.107843 PMid:31518657 DOI: https://doi.org/10.1016/j.diabres.2019.107843

Nazir MA, AlGhamdi L, AlKadi M, AlBeajan N, AlRashoudi L, AlHussan M. The burden of diabetes, its oral complications and their prevention and management. Open Access Maced J Med Sci. 2018;6(8):1545-53. https://doi.org/10.3889/oamjms.2018.294 PMid:30159091 DOI: https://doi.org/10.3889/oamjms.2018.294

ADA. Diabetes care. J Clin Appl Res Educ. 2022;45:1-270.

Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403. https://doi.org/10.1056/NEJMoa012512 PMid:11832527 DOI: https://doi.org/10.1056/NEJMoa012512

Hippisley-Cox J, Coupland C. Diabetes treatments and risk of amputation, blindness, severe kidney failure, hyperglycaemia, and hypoglycaemia: Open cohort study in primary care. BMJ. 2016;352:i1450. https://doi.org/10.1136/bmj.i1450 PMid:27029547 DOI: https://doi.org/10.1136/bmj.i1450

Almdal T, Scharling H, Jensen JS, Vestergaard H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: A population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med. 2004;164(13):1422-6. https://doi.org/10.1001/archinte.164.13.1422 PMid:15249351 DOI: https://doi.org/10.1001/archinte.164.13.1422

ACCP. Standards of practice for clinical pharmacists. Pharmacotherapy. 2014;34(8):794-7. https://doi.org/10.1002/phar.1438 PMid: 25112523 DOI: https://doi.org/10.1002/phar.1438

Tadros L, Ledger-Scott M, Barnes E. The benefits of a pharmacist led type 2 diabetic clinic. Hosp Pharm. 2002;9:6-204.

Hughes JD, Wibowo Y, Sunderland B, Hoti K. The role of the pharmacist in the management of type 2 diabetes: current insights and future directions. Integr Pharm Res Pract. 2017;6:15-27. https://doi.org/10.2147/IPRP.S103783 PMid:29354547 DOI: https://doi.org/10.2147/IPRP.S103783

Alghadeer SM, Alsuwayni B, Almuwayjid AK, Almadi MS, Mubarak AM, Khunayn RM, et al. Glycemic Control and Management in Pharmacist-Led Diabetic Clinic vs. Physician- Led Diabetic Clinic. Medicina (Kaunas). 2021;58(1):14. https://doi.org/10.3390/medicina58010014 PMid:35056322 DOI: https://doi.org/10.3390/medicina58010014

Aguiar PM, da Silva CH, Chiann C, Dorea EL, Lyra DP Jr., Storpirtis S. Pharmacist-physician collaborative care model for patients with uncontrolled type 2 diabetes in Brazil: Results from a randomized controlled trial. J Eval Clin Pract. 2018;24(1):22-30. https://doi.org/10.1111/jep.12606 PMid:27452158 DOI: https://doi.org/10.1111/jep.12606

Abdulrhim SH, Saleh RA, Hussain MA, Al Raey H, Babiker AH, Kheir N, et al. Impact of a collaborative pharmaceutical care service among patients with diabetes in an ambulatory care setting in Qatar: A multiple time series study. Value Health Reg Issues. 2019;19:45-50. https://doi.org/10.1016/j.vhri.2018.12.002 PMid:30875638 DOI: https://doi.org/10.1016/j.vhri.2018.12.002

Alsuwayni B, Alhossan A. Impact of clinical pharmacist-led diabetes management clinic on health outcomes at an academic hospital in Riyadh, Saudi Arabia: A prospective cohort study. Saudi Pharm J. 2020;28(12):1756-9. https://doi.org/10.1016/j.jsps.2020.11.002 PMid:33424266 DOI: https://doi.org/10.1016/j.jsps.2020.11.002

You L, Selvadurai S, Yee C, Noh N, Bao G, Joyce T, et al. Impact of pharmacist-managed Diabetes Medication Therapy Adherence Clinic (DMTAC) in government health clinics. Malays J Pharm Sci. 2015;13(1):43-51.

Shah RD, Braffett BH, Tryggestad JB, Hughan KS, Dhaliwal R, Nadeau KJ, et al. Cardiovascular risk factor progression in adolescents and young adults with youth-onset type 2 diabetes. J Diabetes Complications. 2022;36(3):108123. https://doi.org/10.1016/j.jdiacomp.2021.108123 PMid:35123868 DOI: https://doi.org/10.1016/j.jdiacomp.2021.108123

Jarab AS, Alqudah SG, Mukattash TL, Shattat G, Al-Qirim T. Randomized controlled trial of clinical pharmacy management of patients with type 2 diabetes in an outpatient diabetes clinic in Jordan. J Manag Care Pharm. 2012;18(7):516-26. https://doi.org/10.18553/jmcp.2012.18.7.516 PMid:22971205 DOI: https://doi.org/10.18553/jmcp.2012.18.7.516

Javaid Z, Imtiaz U, Khalid I, Saeed H, Khan RQ, Islam M, et al. A randomized control trial of primary care-based management of type 2 diabetes by a pharmacist in Pakistan. BMC Health Serv Res. 2019;19(1):409. https://doi.org/10.1186/s12913-019-4274-z PMid:31234840 DOI: https://doi.org/10.1186/s12913-019-4274-z

Goruntla N, Mallela V, Nayakanti D. Impact of pharmacist-directed counseling and message reminder services on medication adherence and clinical outcomes in type 2 diabetes mellitus. J Pharm Bioallied Sci. 2019;11(1):69-76. https://doi.org/10.4103/jpbs.JPBS_211_18 PMid:30906142 DOI: https://doi.org/10.4103/JPBS.JPBS_211_18

Kadowaki T, Isendahl J, Khalid U, Lee SY, Nishida T, Ogawa W, et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): A randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022;10(3):193-206. https://doi.org/10.1016/S2213-8587(22)00008-0 PMid:35131037 DOI: https://doi.org/10.1016/S2213-8587(22)00008-0

Zhong P, Zeng H, Huang M, Fu W, Chen Z. Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: A meta-analysis. Endocrine. 2022;75(3):718-24. https://doi.org/10.1007/s12020-021-02945-1 PMid:34981419 DOI: https://doi.org/10.1007/s12020-021-02945-1

Geerling R, Gray SM, Holmes-Truscott E, Speight J. ‘I need someone to believe in me and walk the journey with me’: A qualitative analysis of preferred approaches to weight management discussions in clinical care among adults with type 2 diabetes. Diabet Med. 2022;39(3):e14790. https://doi.org/10.1111/dme.14790 PMid:35030281 DOI: https://doi.org/10.1111/dme.14790

Pousinho S, Morgado M, Placido AI, Roque F, Falcao A, Alves G. Clinical pharmacists’ interventions in the management of type 2 diabetes mellitus: A systematic review. Pharm Pract (Granada). 2020;18(3):2000. https://doi.org/10.18549/PharmPract.2020.3.2000 PMid:32922572 DOI: https://doi.org/10.18549/PharmPract.2020.3.2000

Korcegez EI, Sancar M, Demirkan K. Effect of a Pharmacist- Led Program on Improving Outcomes in Patients with Type 2 Diabetes Mellitus from Northern Cyprus: A Randomized Controlled Trial. J Manag Care Spec Pharm. 2017;23(5):573-82. https://doi.org/10.18553/jmcp.2017.23.5.573 PMid:28448779 DOI: https://doi.org/10.18553/jmcp.2017.23.5.573

Mourao AO, Ferreira WR, Martins MA, Reis AM, Carrillo MR, Guimaraes AG, et al. Pharmaceutical care program for type 2 diabetes patients in Brazil: A randomised controlled trial. Int J Clin Pharm. 2013;35(1):79-86. https://doi.org/10.1007/s11096-012-9710-7 PMid:23161124 DOI: https://doi.org/10.1007/s11096-012-9710-7

Downloads

Published

2022-05-01

How to Cite

1.
AlSubaie N, Alsallal M, AlTwaijri S, AlOtaibi A, AlHarbi B, AlEissa M, Alrashedi R. Impact of Clinical Pharmacist Diabetes Clinic on the Improvement of Health Outcomes in Type 2 Diabetes Subjects. Open Access Maced J Med Sci [Internet]. 2022 May 1 [cited 2024 Mar. 29];10(A):887-92. Available from: https://oamjms.eu/index.php/mjms/article/view/9518